Tvardi Therapeutics (DE:69C)
FRANKFURT:69C
69C Stock Chart & Stats
€2.14
€0.00(0.00%)
At close: 4:00 PM EST
€2.14
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.46 - €37.00
Previous CloseN/A
Volume0.00
Average Volume (3M)104.00
Market Cap
€12.35M
Enterprise Value€4.53M
Total Cash (Recent Filing)€30.81M
Total Debt (Recent Filing)€201.00K
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Aug 13, 2026EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding9,381,344
10 Day Avg. Volume210
30 Day Avg. Volume104
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.61Price Target Upside255.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance SheetVery low reported debt materially reduces near-term refinancing and interest-service risk, giving management more optionality when funding clinical programs. Over a 2–6 month horizon, low leverage supports stability and reduces the probability that operations are immediately constrained by creditors.
Governance / Shareholder ApprovalRecent shareholder approvals and alignment on governance and auditor selection strengthen oversight and investor alignment. Durable governance practices improve credibility with investors and potential partners, supporting fundraising and strategic decisions needed to advance clinical programs over the medium term.
Historically Strong Gross MarginsWhen commercial revenue existed, reported gross margins were high, indicating favorable direct economics for product sales. That structural margin profile suggests potential for attractive profitability if clinical candidates reach commercialization and revenue is re-established, supporting long-term unit economics.
Bears Say
Revenue Collapse To ZeroA complete collapse to zero revenue removes predictability and means the company lacks a commercial cash engine. Over the next several months this increases reliance on external financing and heightens execution risk as program success must replace lost top-line stability to sustain operations and product development.
Persistent Cash BurnConsistent negative operating and free cash flow demonstrates the business does not self-fund development. Continued cash burn will require new capital or partnerships, creating dilution or deal-dependency risks that materially affect the company’s ability to execute multi-year clinical plans without altering program timelines.
Historical Capital Erosion / Negative EquityA recent history of negative equity and shrinking total assets signals prior capital erosion and constrained financial flexibility. Even with low debt now, past balance sheet weakness increases the chance management must rely on dilutive financings or unfavorable partner terms to fund development over the medium term.
Tvardi Therapeutics News
69C FAQ
What was Tvardi Therapeutics’s price range in the past 12 months?
Tvardi Therapeutics lowest stock price was €1.46 and its highest was €37.00 in the past 12 months.
What is Tvardi Therapeutics’s market cap?
Tvardi Therapeutics’s market cap is €12.35M.
When is Tvardi Therapeutics’s upcoming earnings report date?
Tvardi Therapeutics’s upcoming earnings report date is Aug 13, 2026 which is in 47 days.
How were Tvardi Therapeutics’s earnings last quarter?
Currently, no data Available
Is Tvardi Therapeutics overvalued?
According to Wall Street analysts Tvardi Therapeutics’s price is currently Undervalued.
Does Tvardi Therapeutics pay dividends?
Tvardi Therapeutics does not currently pay dividends.
What is Tvardi Therapeutics’s EPS estimate?
Tvardi Therapeutics’s EPS estimate is -0.61.
How many shares outstanding does Tvardi Therapeutics have?
Tvardi Therapeutics has 9,381,344 shares outstanding.
What happened to Tvardi Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tvardi Therapeutics?
Currently, no hedge funds are holding shares in DE:69C
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tvardi Therapeutics
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
69C Stock 12 Month Forecast
Average Price Target
€7.61
▲(255.46% Upside)
Technical Analysis
Plus Therapeutics
―
Cue Biopharma
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Adlai Nortye Ltd. Sponsored ADR
―
Options Prices
Currently, No data available
---